Lantern-master.png
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
June 29, 2020 08:45 ET | Lantern Pharma
The machine learning-powered RADR® platform identifies genomically distinct cancer subtypes, and patient groups, that can respond to specific drugs that Lantern and its partners are developingThe...
Lantern-master.png
Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
June 17, 2020 09:23 ET | Lantern Pharma
DALLAS, June 17, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic...
Lantern-master.png
Lantern Pharma Announces Closing of Initial Public Offering
June 15, 2020 15:53 ET | Lantern Pharma
DALLAS, June 15, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning...
Lantern-master.png
Lantern Pharma Announces Pricing of Initial Public Offering
June 10, 2020 19:07 ET | Lantern Pharma
DALLAS, June 10, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and...
Lantern-master.png
Lantern Pharma Appoints David Margrave as Chief Financial Officer and Kishor Bhatia, Ph.D., as Chief Scientific Officer
December 17, 2019 08:30 ET | Lantern Pharma
DALLAS and KEARNY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of David Margrave as Chief...
Lantern-master.png
Lantern Pharma Expands and Strengthens Board of Directors with Healthcare and Pharma Industry Veterans Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D.
December 11, 2019 09:00 ET | Lantern Pharma
DALLAS and KEARNY, N.J., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of two new members, Franklyn...
Lantern-master.png
Lantern Pharma CEO Panna Sharma to Present & Participate in Panel Discussion at AI Applications in Biopharma Summit 2019 in Boston
November 07, 2019 08:00 ET | Lantern Pharma
DALLAS and KEARNY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI, machine learning (ML) and genomics, today announced its Chief Executive...
Lantern-master.png
Lantern Pharma Selects Reprocell Inc. to Provide Preclinical Screening and Biomarker Discovery Services for Portfolio of Targeted Oncology Drugs
October 29, 2019 08:00 ET | Lantern Pharma
DALLAS and KEARNY, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging A.I., machine learning (ML) and genomics, announced today that it has selected...
Lantern-master.png
Lantern Pharma CEO Panna Sharma to Speak at Bio Data World West 2019
October 07, 2019 08:00 ET | Lantern Pharma
DALLAS and KEARNY, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced its Chief Executive Officer, Panna Sharma,...
Lantern-master.png
Lantern Pharma and National Cancer Institute Partner to Aid Precision Oncology Research and Treatments
October 01, 2019 08:00 ET | Lantern Pharma
DALLAS and KEARNY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced a collaboration agreement with the...